Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

R.L. Coleman; A.M. Oza; D. Lorusso; C. Aghajanian; A. Oaknin; A. Dean; N. Colombo; J.I. Weberpals; A. Clamp; G. Scambia; A. Leary; R.W. Holloway; M.A. Gancedo; P.C. Fong; J.C. Goh; D.M. O'Malley; D.K. Armstrong; J. Garcia-Donas; E.M. Swisher; A. Floquet; G.E. Konecny; I.A. McNeish; C.L. Scott; T. Cameron; L. Maloney; J. Isaacson; S. Goble; C. Grace; T.C. Harding; M. Raponi; J. Sun; K.K. Lin; H. Giordano; J.A. Ledermann

doi:10.1016/S0140-6736(17)32440-6

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

R.L. Coleman, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J.I. Weberpals, A. Clamp, G. Scambia, A. Leary, R.W. Holloway, M.A. Gancedo, P.C. Fong, J.C. Goh, D.M. O'Malley, D.K. Armstrong, J. Garcia-Donas, E.M. Swisher, A. FloquetG.E. Konecny, I.A. McNeish, C.L. Scott, T. Cameron, L. Maloney, J. Isaacson, S. Goble, C. Grace, T.C. Harding, M. Raponi, J. Sun, K.K. Lin, H. Giordano, J.A. Ledermann

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1949-1961
Number of pages	13
Journal	The Lancet
Volume	390
Issue number	10106
DOIs	https://doi.org/10.1016/S0140-6736(17)32440-6
Publication status	Published - 2017

Access to Document

10.1016/S0140-6736(17)32440-6

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029218556&doi=10.1016%2fS0140-6736%2817%2932440-6&partnerID=40&md5=7d83e1df812a36c5220e6bcd33e3325d

Cite this

Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., Leary, A., Holloway, R. W., Gancedo, M. A., Fong, P. C., Goh, J. C., O'Malley, D. M., Armstrong, D. K., Garcia-Donas, J., Swisher, E. M., ... Ledermann, J. A. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 390(10106), 1949-1961. https://doi.org/10.1016/S0140-6736(17)32440-6

Coleman, RL, Oza, AM, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, JI, Clamp, A, Scambia, G, Leary, A, Holloway, RW, Gancedo, MA, Fong, PC, Goh, JC, O'Malley, DM, Armstrong, DK, Garcia-Donas, J, Swisher, EM, Floquet, A, Konecny, GE, McNeish, IA, Scott, CL, Cameron, T, Maloney, L, Isaacson, J, Goble, S, Grace, C, Harding, TC, Raponi, M, Sun, J, Lin, KK, Giordano, H & Ledermann, JA 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, vol. 390, no. 10106, pp. 1949-1961. https://doi.org/10.1016/S0140-6736(17)32440-6

@article{25cb67f2d3764f7f94d61ea1667a06ce,

title = "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial",

author = "R.L. Coleman and A.M. Oza and D. Lorusso and C. Aghajanian and A. Oaknin and A. Dean and N. Colombo and J.I. Weberpals and A. Clamp and G. Scambia and A. Leary and R.W. Holloway and M.A. Gancedo and P.C. Fong and J.C. Goh and D.M. O'Malley and D.K. Armstrong and J. Garcia-Donas and E.M. Swisher and A. Floquet and G.E. Konecny and I.A. McNeish and C.L. Scott and T. Cameron and L. Maloney and J. Isaacson and S. Goble and C. Grace and T.C. Harding and M. Raponi and J. Sun and K.K. Lin and H. Giordano and J.A. Ledermann",

note = "Cited By :7 Export Date: 2 March 2018",

year = "2017",

doi = "10.1016/S0140-6736(17)32440-6",

language = "English",

volume = "390",

pages = "1949--1961",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "10106",

}

TY - JOUR

T1 - Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

AU - Coleman, R.L.

AU - Oza, A.M.

AU - Lorusso, D.

AU - Aghajanian, C.

AU - Oaknin, A.

AU - Dean, A.

AU - Colombo, N.

AU - Weberpals, J.I.

AU - Clamp, A.

AU - Scambia, G.

AU - Leary, A.

AU - Holloway, R.W.

AU - Gancedo, M.A.

AU - Fong, P.C.

AU - Goh, J.C.

AU - O'Malley, D.M.

AU - Armstrong, D.K.

AU - Garcia-Donas, J.

AU - Swisher, E.M.

AU - Floquet, A.

AU - Konecny, G.E.

AU - McNeish, I.A.

AU - Scott, C.L.

AU - Cameron, T.

AU - Maloney, L.

AU - Isaacson, J.

AU - Goble, S.

AU - Grace, C.

AU - Harding, T.C.

AU - Raponi, M.

AU - Sun, J.

AU - Lin, K.K.

AU - Giordano, H.

AU - Ledermann, J.A.

N1 - Cited By :7 Export Date: 2 March 2018

PY - 2017

Y1 - 2017

U2 - 10.1016/S0140-6736(17)32440-6

DO - 10.1016/S0140-6736(17)32440-6

M3 - Article

SN - 0140-6736

VL - 390

SP - 1949

EP - 1961

JO - The Lancet

JF - The Lancet

IS - 10106

ER -